US EditionNovo Nordisk says Alzheimer's drug trial fails, hammering shares
Two phase 3 trials involving 3,808 early Alzheimer's patients showed oral semaglutide improved biomarkers but did not slow cognitive decline, prompting discontinuation of follow-up studies.
- On Monday, Novo Nordisk announced that its oral semaglutide pill Rybelsus failed to meet the primary goal in two phase 3 trials, Evoke and Evoke+, enrolling more than 3,800 adults with early-stage Alzheimer's.
- Driven by prior midstage and preclinical evidence, Novo Nordisk pursued the Alzheimer’s programme despite Martin Holst Lange acknowledging it carried a low likelihood of success.
- Using the 14 mg once-daily dose , the trials measured cognition over a two-year follow-up period with CDR-SB and aimed for 20% slowing, but Novo said only secondary and exploratory endpoints and biomarkers showed signals while discontinuing one-year extensions.
- Shares reacted immediately, with the stock tumbling about 10% on Monday, as analysts see the setback as another blow to Novo Nordisk shares under CEO Mike Doustdar amid restructuring.
- High-Level results are slated for Dec. 3 in San Diego at the CTAD conference, with full data in March at AD/PD; analysts say the outcome reshapes competition for Biogen and matters for more than 55 million people affected globally.
120 Articles
120 Articles
Danish pharmaceutical giant Novo Nordisk is taking revenge on the Copenhagen Stock Exchange after Monday's price drop. The share is bouncing back and is up almost 4 percent on Tuesday afternoon. Just as in connection with Monday's decline, it is the results of a newly published study that is causing the share to react strongly. The company has announced a positive result for...
Ozempic does not slow Alzheimer’s, study finds
Ozempic does not slow Alzheimer’s progression, its manufacturer Novo Nordisk said following a two-year study. The popular drug reduces body weight by on average around 15% in obese patients, and early data suggested it may also slow the progress of some brain conditions, along with cancer, heart disease, liver, and kidney problems. The question had always been how much those changes were consequences of reducing obesity, or a confounding effect:…
The actions listed on the U.S. Novo Nordisk bridge, the European producer of Ozempic and Wegovy drugs, fell by over 5%, reaching a minimum of the last four years on the basis of the...
Why Novo Nordisk Stock Sank 5.6% Today
Key PointsNovo Nordisk's Phase II trial found that semaglutide did not slow Alzheimer's progression.The setback comes as competition heats up in the obesity and diabetes drug market.10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq Composite gained 1.5% and 2.6%, respectively. The Danish drugmaker's stock slumped after the company anno…
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
(MedPage Today) -- The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared topline results from the 2-year...
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
